$2.63
+1.15%Oct 19, 2026, 12:30 UTC
NRx Pharmaceuticals announced completion of three commercial-condition process-validation lots of preservative-free ketamine ahead of the November 10 GDUFA goal date.
Source:Oct 15, 2026, 12:27 UTC
The FDA issued NRX Pharmaceuticals, Inc. a labeling review letter for preservative-free ketamine, classifying all requested changes as minor and requesting labels using the proprietary name under FDA review.
Source:Sep 30, 2026, 11:00 UTC
NRx Defense Systems, an NRx company, was awarded an $11 million DARPA prime contract to evaluate robotic magnetic stimulation combined with NRX-101 for treatment-resistant depression.
Source:Sep 15, 2026, 19:11 UTC
The FDA Office of Generic Drugs reclassified NRx Pharmaceuticals' amendment to its Abbreviated New Drug Application for preservative-free ketamine from a Major Amendment to a Minor Amendment.
Source:Sep 14, 2026, 11:00 UTC
GeNeuro, Inc., an NRx company, was awarded European patent rights for GNK-301, a novel drug candidate for treating amyotrophic lateral sclerosis (ALS).
Source:Sep 11, 2026, 11:00 UTC
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, began training staff and will be the first interventional psychiatry provider to deploy Zeta Surgical's FDA-cleared Zeta TMS Robotic System in Florida.
Source:Aug 17, 2026, 11:00 UTC
NRx Pharmaceuticals completed the first-cycle FDA review of its ANDA for preservative-free ketamine with no drug-related major deficiencies, and submitted the sole remaining manufacturer's attestation on the vial to the FDA.
Source:Aug 15, 2026, 01:16 UTC
NRx Pharmaceuticals, Inc. reported a Q2 2026 loss of $0.18 per share, missing the Zacks Consensus Estimate of a loss of $0.09, and compared to a loss of $0.98 per share a year ago.
Source:Aug 10, 2026, 14:05 UTC
NRx Pharmaceuticals completed the first-cycle FDA review of its abbreviated new drug application for preservative-free ketamine, with one remaining issue related to the product's vial connector.
Jun 25, 2026, 11:00 UTC
NRx Pharmaceuticals subsidiary HOPE Therapeutics began treating first patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System at clinics in West Palm Beach and Sarasota, Florida.
Source:Jun 24, 2026, 17:18 UTC
Kadima Neuropsychiatry Institute and Dr. David Feifel filed a lawsuit against NRx Pharmaceuticals, its subsidiary Hope Therapeutics Inc., and HTX Management Company LLC in San Diego County Superior Court, alleging breach of contract and misrepresentation related to an acquisition agreement.
Source:Jun 23, 2026, 15:05 UTC
ZETA SURGICAL and HOPE Therapeutics treated the first patient with the Zeta TMS Navigation System at a HOPE Therapeutics clinic in Sarasota, Florida.
Jun 22, 2026, 11:00 UTC
The FDA granted an expanded access protocol for NRx Pharmaceuticals' NRX-101 to augment transcranial magnetic stimulation in treating depression.
Source:Jun 4, 2026, 21:12 UTC
NRx Pharmaceuticals closed a $22.3 million underwritten public offering of common stock, including the exercise of the underwriters' option.